See the DrugPatentWatch profile for tzield
Yes, Tezspire (Teplizumab) Delays Type 1 Diabetes Onset
Tezspire (teplizumab-tzld), branded as Tzield, is FDA-approved to delay the onset of stage 3 type 1 diabetes in adults and children aged 8 and older with stage 2 disease. It targets autoimmune destruction of insulin-producing beta cells by binding to CD3 on T cells, slowing progression from presymptomatic to clinical stage 3 diabetes.[1][2]
How Tzield Works and Who Qualifies
Tzield is a monoclonal antibody given as a 14-day intravenous course. It reduces beta cell stress and preserves function, delaying diagnosis by a median of 2-3 years in trials. Eligible patients show two or more type 1 diabetes autoantibodies, abnormal glucose tolerance (but not yet diabetic), and no prior insulin use.[1][3]
Clinical Trial Results
In the pivotal TN-10 trial (262 patients), 43% of Tzield-treated patients delayed stage 3 onset by at least 2 years, versus 26% on placebo. Median delay was 40 months. Real-world data from PROTZD shows similar delays up to 4 years in some cases.[2][4]
When Does Treatment Start and What Are the Limits?
Administer within 6 months of stage 2 diagnosis confirmation. It's a one-time course; repeat use lacks approval. Not for those with stage 3 diabetes or allergies to teplizumab.[1]
Common Side Effects Patients Report
Rash (affects 50%+), fever, nausea, and lymphopenia occur frequently. Serious risks include infections, hypersensitivity, and cytokine release syndrome. Monitoring includes weekly bloodwork during infusion.[1][3]
Cost and Access Details
A single course costs about $200,000-$250,000 before insurance. Patient assistance programs from Provention Bio (now Sanofi) cover copays for eligible insured patients. Medicare Part B often reimburses.[5]
Alternatives to Tzield for Delaying Type 1 Diabetes
No other FDA-approved drugs delay onset. Options include:
- Low-dose atorvastatin or IL-2 (experimental, not approved).
- Lifestyle interventions like vitamin D or omega-3s (limited evidence).
- Stem cell therapies (e.g., Vertex VX-880) for established disease.[6]
Patent Status and Biosimilar Outlook
Provention Bio holds key patents on teplizumab composition and use until at least 2033-2036. No active challenges listed; generics unlikely before expiry.[7]
Sources
[1]: FDA Label for Tzield
[2]: NEJM Trial Publication
[3]: ADA Guidelines on Screening
[4]: TrialNet PROTZD Study
[5]: GoodRx Pricing
[6]: JDRF Research Summary
[7]: DrugPatentWatch.com - Teplizumab Patents